Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Category
Cancer
Sub Category
Gastrointestinal
Study Name
S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Principal Investigator
Gordan Srkalovic MD, PhD
Study Information
A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Contact for Questions
Nurse - Tracy 517-364-2835

Site view: at a glance